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Indomethacin, Alone and Combined With Prochlorperazine and
Caffeine, but not Sumatriptan, Abolishes Peripheral and Central
Sensitization in In Vivo Models of Migraine
Carla Ghelardini,* Nicoletta Galeotti,* Irene Grazioli,† and Carla Uslenghi†
Abstract: Recently it has been proposed that the throbbing pain of migraine is mediated by
sensitization of peripheral trigeminovascular neurons, and that cutaneous allodynia of migraine is
mediated by sensitization of central trigeminovascular neurons, and, moreover, that the triptans are
less effective in aborting a migraine attack if the central sensitization is already established. The
combination of indomethacin, prochlorperazine, and caffeine (IndoProCaf) is a drug of well-estab-
lished use in the acute treatment of migraine. The aim of this study was to investigate whether the
3 active principles of IndoProCaf, alone and combined, compared to sumatriptan, were able to abolish
the peripheral sensitization induced by kainic acid and the central sensitization induced by N-methyl-
D-aspartate (NMDA) in in vivo models of hyperalgesia. The study showed that indomethacin or
IndoProCaf is able to abolish both the kainic acid–induced and the NMDA-induced hyperalgesia. If
administered at different times, IndoProCaf was always effective in reversing the kainic acid-induced
hyperalgesia. Sumatriptan was not able to reverse either the kainic acid–induced or the NMDA-
induced hyperalgesia. The efficacy of indomethacin, alone and combined with prochlorperazine and
caffeine, in abolishing peripheral and central sensitization in in vivo models of hyperalgesia is a
further explanation of the clinical efficacy of IndoProCaf in the treatment of migraine.
Perspective: This study suggests that, although triptans were shown to be able to abort migraine
attacks only if given before the establishment of cutaneous allodynia and central sensitization, Indo-
ProCaf should be able to abort migraine attacks independently from the time of administration,
because it is able to abolish an already established peripheral and central sensitization.
© 2004 by the American Pain Society
Key words: Indomethacin, prochlorperazine, caffeine, sumatriptan, migraine.
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migraine is a common, multifactorial, neurovas-
cular disorder, characterized by recurrent dis-
abling attacks of moderate to severe headache,
ausea, vomiting, photophobia, and phonophobia, and
lso, in up to one third of patients, neurologic aura
ymptoms.12 It is known thatmigraine is characterized by
state of central neuronal hyperexcitability,30 which in-
olves overactivity of the excitatory amino acids. Higher
oncentrations of excitatory amino acids (mainly glu-
amic and aspartic acid) were observed in the cerebrospi-
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The Journal of Pain, Vol 5, No 8 (Oal fluid,23 in the saliva,26 in the plasma,2,13 and in the
latelets9 of patients with migraine.
Recently it has been proposed that the throbbing pain
f migraine, which is the pulsating pain aggravated by
outine physical activities, is mediated by sensitization of
eripheral trigeminovascular neurons, and that cutane-
us allodynia (CA) of migraine, which means pain result-
ng from a non-noxious stimulus to normal skin, is medi-
ted by sensitization of central trigeminovascular
eurons.4,22
The development of hyperalgesia has been shown af-
er the injection of kainic acid. The hyperalgesic effect of
ainic acid appears to be mediated by activity at amino–
ethylisoxazole-propionic acid/kainate receptors that
re located outside the spinal cord, perhaps on primary
fferents in trigeminal ganglia.27 Intraperitoneal injec-
ion of kainic acid induces a persistent hyperalgesia in
ice and rats.18Glutamate, an excitatory neurotransmitter, produces
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414 IndoProCaf Abolishes Sensitizationts action by acting on N-methyl-D-aspartate (NMDA) re-
eptors. It has been demonstrated in rats that NMDA
eceptors mediate the synaptic transmission of the pe-
ipheral trigeminovascular neurons in central trigeminal
ubnucleus caudalis.1 NMDA receptors play a key role in
he nociceptive transmission within the spinal cord, as
videnced by the short duration hyperalgesia induced by
he intrathecal injection of NMDA in mice and rats.21,29
Sumatriptan is the first commercially available and
ost widely prescribed of the serotonin 5-HT1B/1D ago-
ists known as triptans. Sumatriptan is considered the
old standard in controlled trials of drugs used in the
cute treatment of migraine.12 However, it has recently
een shown that the triptans are less effective in abort-
ng a migraine attack if the central sensitization is al-
eady established.5
The combination of indomethacin, prochlorperazine,
nd caffeine (IndoProCaf) is a drug of well-established use
n Italywitha recognizedefficacy andagood level of safety
n the acute treatment of migraine. Each active ingredient
f IndoProCaf has specific antimigraine properties. Differ-
ntly from other nonsteroidal anti-inflammatory drugs
NSAIDs), indomethacin is structurally related to serotonin
nd has central analgesic and cranial vasoconstrictor prop-
rties.19,28 Prochlorperazine is a phenothiazine antiemetic,
ndowed with analgesic properties mediated by the pre-
ynaptic inhibitionof theD2heteroreceptor locatedon the
holinergic neurons.16 Caffeine induces central cholinergic
nalgesia.15
Recently in a multicenter, randomized, crossover clini-
al trial, IndoProCaf was shown to be significantly more
ffective than sumatriptan in the acute treatment of mi-
raine attacks.10 The aim of this study was to investigate
hether the 3 active principles of IndoProCaf, alone and
ombined, compared to sumatriptan, were able to abol-
sh the peripheral sensitization induced by kainic acid
nd the central sensitization induced by NMDA in in vivo
odels of hyperalgesia.
aterials and Methods
nimals
Male albino mice (20 to 25 g) from Morini breeding
arm (San Polo d’Enza, Italy) were used. All experiments
ere carried out according to the guidelines of the
uropean Community Council Directive dated November
4, 1986 (86/609/EEC) for experimental animal care. All
fforts were made to minimize suffering and to reduce
he number of animals used.
rugs
The following drugs were used: indomethacin (NSAID;
igma, Milan, Italy), prochlorperazine (D2-antagonist;
igma), caffeine (adenosine antagonist; Sigma),
umatriptan (5-HT1B/1D agonist; GlaxoSmithKline, Ve-
ona, Italy), kainic acid (kainate receptor agonist; Sigma),
MDA receptor agonist (Sigma), oxotremorine (musca-
inic agonist; Fluka, Milan, Italy), baclofen (GABAB-ago-
ist; R.B.I., Milan, Italy), amitriptyline (tricyclic antide- rressant; Sigma), and diclofenac (NSAID; Sigma). The
oses of the drugs tested in this study were able to re-
erse othermodels of hyperalgesia andweremuch lower
han those shown to be analgesic in the hot plate
est14,17: indomethacin (0.1 mg/kg intraperitoneal), pro-
hlorperazine (0.1 mg/kg intraperitoneal), caffeine (0.3
g/kg intraperitoneal), and sumatriptan (1 mg/kg intra-
eritoneal). The doses of the drugs tested as negative
eference drugs were not antinociceptive in the hot
late test14: oxotremorine (0.01 mg/kg intraperitoneal),
aclofen (0.2 mg/kg intraperitoneal), amitriptyline (0.5
g/kg intraperitoneal), and diclofenac (1 mg/kg intra-
eritoneal).
Indomethacin, prochlorperazine, and caffeine
alone and combined), sumatriptan, oxotremorine, ba-
lofen, amitriptyline, and diclofenac were intraperito-
eally administered to reach the respective analgesic
eak in correspondence with the hot plate test.14 Ac-
ording to the specific pharmacokinetic properties, the
rugs were administered 45 minutes (prochlorpera-
ine), 30 minutes (baclofen, amitriptyline, and diclofe-
ac), or 15 minutes (sumatriptan, caffeine, and ox-
tremorine) before the hot plate test. Indomethacin,
lone and combined with prochlorperazine and caf-
eine, was administered 15, 30, and 45 minutes before
he hot plate test.
ainic Acid–Induced Hyperalgesia
According to Giovengo et al,18 kainic acid–induced hy-
eralgesia was obtained through intraperitoneal admin-
stration of kainic acid (20mg/kg) at least 48 hours before
he hot plate test. Because the intraperitoneal injection
f kainic acid produces a long-term thermal hyperalge-
ia, when tested with the hot plate (mice) and tail flick
mice and rats) assays, and mechanical hyperalgesia,
hen tested with von Frey filaments (rats), whereas,
hen injected intrathecally, it fails to induce hyperalge-
ia, it seems unlikely that the brain is the site of action of
ainic acid.18 Thus this model should be considered an
xample of peripheral sensitization, because of the phar-
acologic effects of kainic acid and the route of admin-
stration. The reduction of pain threshold reaches the
eak 24 hours after the injection of kainic acid, and the
ffect lasts for several days. The drugswere administered
hen the hyperalgesia was already established; there-
ore the kainic acid–induced hyperalgesia should be con-
idered amodel of treatment of peripheral sensitization.
MDA-Induced Hyperalgesia
Hyperalgesia was induced by the intrathecal adminis-
ration of NMDA (1.64 g/mouse) 15 minutes before the
ot plate test. Intrathecal injections were performed un-
er ether anesthesia as described by Hylden and Wil-
ox.20 The mouse was gently restrained, and a 30-gauge,
/2-inch needle mated to a 50-L Hamilton syringe was
nserted between L5 and L6 of the mouse spinal column.
volume of 5 L was used for intrathecal injection. Be-
ause of the pharmacologic effects of NMDA and the
oute of administration, this model should be considered
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415ORIGINAL REPORT/Ghelardini et aln example of central sensitization. The drugs were ad-
inistered before or simultaneously with the NMDA;
owever, the maximal effect of NMDA on the licking
atency was observed a few minutes after the adminis-
ration. Therefore, the NMDA-induced hyperalgesia
hould be considered a model of treatment of central
ensitization.
ot Plate Test
The hyperalgesia was evaluated through the hot
late test. The method adopted was described by
’Callaghan and Holtzman.24 Mice were placed inside
stainless steel container, thermostatically set at
2.5°C  0.1°C in a precision water-bath (KW Mechan-
cal Workshop, Siena, Italy). Reaction times (seconds)
ere measured with a stopwatch before (pretest) and
fter treatment. The end point used was the licking of
he fore or hind paws. Those mice scoring less than 12
nd more than 18 seconds in the pretest were rejected
30%). An arbitrary cutoff time of 45 seconds was
dopted.
tatistics
Results are given as themean standard error ofmean
SEM); the analysis of variance was used to verify the
ignificance between 2 means, followed by Fisher pro-
ected least significant difference procedure for post hoc
omparison. P values of less than .05 were considered
ignificant. Data were analyzed with the StatView for
he Macintosh computer program (1992; SAS Institute,
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Drugs
igure 1. Effect of analgesic drugs (indomethacin, prochlorper
iclofenac) on hyperalgesia induced by kainic acid (20 mg/kg in
ean of at least 8 mice. All data are mean  SEM. *P  .01, ^Pnc, Cary, NC).esults
yperalgesia Induced by Kainic Acid
Indomethacin was able to abolish the hyperalgesia in-
uced by kainic acid. Indomethacin was able to reverse
he decrease of licking latency observedwith kainic acid–
reated mice when administered 15 minutes (P  .05)
nd 30 minutes (P .01) before the hot plate test (Fig 1).
Prochlorperazine was also able to reverse the kainic
cid–induced hyperalgesia (P  .05) when administered
5 minutes before the hot plate test. Caffeine was not
ble to reverse the kainic acid–induced hyperalgesia.
IndoProCaf was able to reverse the kainic acid–induced
yperalgesia when administered 15, 30 (P  .01), and 45
inutes (P  .05) before the hot plate test (Fig 2).
Sumatriptan was not able to reverse the kainic acid–
nduced hyperalgesia.
Other analgesic drugs (oxotremorine, baclofen, am-
triptyline, and diclofenac), tested as negative refer-
nce drugs, were not able to reverse this type of hy-
eralgesia (Fig 1).
yperalgesia Induced by NMDA
Indomethacin was able to abolish the hyperalgesia
nduced by NMDA. Indomethacin was able to reverse
he decrease of licking latency observed with NMDA-
reated mice when administered 15 (P  .05) and 30
inutes (P  .01) before the hot plate test (Fig 3).
Prochlorperazine and caffeinewere not able to reverse
he NMDA-induced hyperalgesia.
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416 IndoProCaf Abolishes Sensitizationyperalgesia when administered 15 and 30 minutes
efore the hot plate test (P  .01) (Fig 4).
Sumatriptan was not able to reverse the NMDA-
nduced hyperalgesia. Diclofenac was also able to re-
erse the NMDA-induced hyperalgesia (P  .05).
Other analgesic drugs (oxotremorine, baclofen, and
mitriptyline), tested as negative reference drugs, were
ot able to reverse this type of hyperalgesia (Fig 3).
iscussion
The aim of this study was to investigate whether the 3
ctive principles of IndoProCaf, alone and combined,
igure 2. Effect of IndoProCaf (indomethacin 0.1 mg/kg, pro-
hlorperazine 0.1 mg/kg, caffeine 0.3 mg/kg intraperitoneal) on
yperalgesia induced by kainic acid (20 mg/kg intraperitoneal)
n mouse hot plate test. Each column represents the mean of at
east 10 mice. All data are mean  SEM. *P  .01, ^P  .05 vs
ainic acid only treated mice.
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igure 3. Effect of analgesic drugs (indomethacin, prochlorper
iclofenac) on hyperalgesia induced by intrathecal administration o
epresents the mean of at least 8 mice. All data are mean  SEM. *Pompared to sumatriptan, were able to abolish the pe-
ipheral sensitization induced by kainic acid and the cen-
ral sensitization induced by NMDA in in vivo models of
yperalgesia.
The study showed that indomethacin, alone and com-
ined with prochlorperazine and caffeine, but not
umatriptan, is able to abolish the peripheral hyperalge-
ia induced by kainic acid and the central hyperalgesia
nduced by NMDA.
The study also showed that prochlorperazine is able to
bolish the kainic acid–induced hyperalgesia, and that
NMDA
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417ORIGINAL REPORT/Ghelardini et aliclofenac is able to reverse the NMDA-induced hyperal-
esia.
Other analgesic drugs, which are not indicated for the
reatment ofmigraine, were not able to abolish this type
f sensitization.
These results are consistent with previous data show-
ng that the intrathecal injection of indomethacin is able
o reduce the hyperalgesia induced by NMDA.25,32 How-
ver, in these previous experiments indomethacin was
entrally (intrathecally) injected, whereas in the present
tudy it was peripherally (intraperitoneally) adminis-
ered. The efficacy of diclofenac, a NSAID, in reversing
he NMDA-induced hyperalgesia could be expected, con-
idering that it is known that prostaglandins and nitric
xide mediate this type of hyperalgesia.25 Why indo-
ethacin, and not diclofenac, was able to reverse kainic
cid–induced hyperalgesia is not known.
If administered at different times, IndoProCaf was
lways effective in reversing the kainic acid–induced
yperalgesia. In a previous study, IndoProCaf was
ound to be able to abolish almost completely the ab-
ominal constrictions induced by the intraperitoneal
njection of a 0.3% solution of acetic acid, with a sig-
ificantly higher efficacy compared to the single active
rinciples.14
In this study, sumatriptan was not able to reverse the
ainic acid–induced peripheral sensitization or the
MDA-induced central sensitization.
This result confirms that triptans cannot abolish al-
eady established central sensitization,5,7 but it also sug-
ests that triptans cannot abolish already established pe-
ipheral sensitization.
The in vivo models used in this study are clinically im-
ortant, because they evidenced different effects of In-
oProCaf and sumatriptan. On the contrary, in another
n vivo model of migraine both IndoProCaf and
umatriptan, at the same doses used in this study, were
ctive in reversing hyperalgesia induced by morphine
ithdrawal.14,17
The dosages used for IndoProCaf in these experi-
ental models (indomethacin 0.1 mg/kg, prochlor-
erazine 0.1 mg/kg, and caffeine 0.3 mg/kg) are 10
imes lower than those shown to be analgesic in the
ot plate test.14 It is important to note that the ther-
peutic dose (orally or rectally administered) of indo-
ethacin contained in IndoProCaf as antimigraine
rug is 25 to 50 mg, a lower dose compared to the
ntirheumatic dosage, and that of prochlorperazine is
to 8 mg, a lower dose compared to the antipsychotic
nd antiemetic dosage. These findings confirm that
igraine is a particular pain characterized by neuronal
yperexcitability, and that migraine should be treated
ith specific drugs at dosages that could be subanal-
esic but antihyperalgesic.
The efficacy of indomethacin, prochlorperazine, and
ndoProCaf in reversing the kainic acid–induced hyper-
lgesia is clinically important, when considering the
ypothesis that peripheral sensitization is a common
eature of migraine patients, whose throbbing and
ulsating pain is aggravated by routine physical activ- tties such as climbing stairs and bending over or by
oughing.8 The efficacy of indomethacin and IndoPro-
af in abolishing the NMDA-induced hyperalgesia is
lso clinically relevant, when considering that central
ensitization is suggested to lead to CA, meaning that
n 79% of migraine patients an innocuous stimulation
f the skin, such as brushing hair, touching the scalp,
r wearing glasses, is perceived as painful during the
igraine attack.8
Recently the hyperexcitability that develops along
he trigeminovascular pain pathway during a migraine
ttack has been studied in humans. It has been sug-
ested that a few minutes after the onset of migraine,
he peripheral nociceptors become sensitized, and the
eadache starts to throb; afterwards, the barrage of
mpulses that come from the peripheral nociceptors
ctivate second-order neurons in the nucleus caudalis
nd initiate their sensitization, mediating the develop-
ent of CA on the ipsilateral head. Then the barrage
f impulses that come from the hyperactive second-
rder neurons sensitizes third-order thalamic neurons,
ediating the development of CA on the contralateral
ead and ipsilateral forearm over 1 hour after the ap-
earance of allodynia on the ipsilateral head.6 More-
ver, the efficacy of triptan therapy in patients with or
ithout CA, defined by differences between migraine
nd baseline pain thresholds to mechanical and ther-
al stimulation of periorbital skin, has been investi-
ated.5 Triptan treatment of migraine was equally in-
ffective once CA was present and equally effective in
he absence of CA. In patients with CA, triptan treat-
ent was far more effective if given before rather
han after CA developed. Furthermore, in an animal
odel of central sensitization induced by topical ap-
lication of inflammatory soup on the dura, early en-
ovenous sumatriptan treatment blocked the devel-
pment of central sensitization; on the other hand,
ate sumatriptan treatment did not reverse central
ensitization such as response threshold to heating of
he skin.7
The clinical implication of these recent findings is
hat patients with CA should take triptan therapy as
oon as possible after onset of migraine, because
riptans were shown to be able to abort migraine at-
acks only if given before the establishment of CA and
entral sensitization. On the contrary, IndoProCaf
hould be able to abort migraine attacks indepen-
ently from the time of administration, because this
xed combination is able to abolish an already estab-
ished peripheral and central sensitization. It has to be
onsidered that the model of NMDA-induced central
yperalgesia is not analogous to the animal model
sed to evaluate the effects of triptans on central sen-
itization.7
The efficacy of indomethacin and IndoProCaf in
bolishing the central hyperalgesia induced by NMDA
ould have a potential therapeutic value, when con-
idering that NMDA is involved in long-term potentia-
ion and that in patients with tension-type headache
he development of central sensitization could lead to
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418 IndoProCaf Abolishes Sensitizationhronic headache.3 Recently in a double-blinded, ran-
omized, nimesulide-controlled, multicenter clinical
rial, IndoProCaf was shown to be very effective in the
reatment of episodic tension-type headache (Cerbo et
l, unpublished data).
Moreover, neuronal hyperexcitability is involved not
nly in migraine but also in neuropathic pain, a pain
aused by a lesion of the peripheral and/or central
ervous system.11 The role that central sensitization
nd the NMDA receptor have in pathological pain is
ighlighted by studies that show that the blocking of
t
serotonin, 5-HT1B/1D agonists) inmigraine: Detailed results
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2entral sensitization with NMDA antagonists abolishes
ain hypersensitivity in patients with neuropathic pain.31
In conclusion, the efficacy of indomethacin, alone
nd combined with prochlorperazine and caffeine, in
bolishing peripheral and central sensitization in in
ivo models of hyperalgesia is a further explanation of
he clinical efficacy of IndoProCaf in the treatment of
igraine. Furthermore, these results support the ratio-
ale for exploring the clinical efficacy of IndoProCaf in
he treatment of other types of pain in humans.eferences
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